NIH and FDA envision transforming the way clinical trials are done across the biomedical research enterprise.
The House is on track to join the Senate in rejecting the Trump administration’s budget proposal that would cut NIH by $18 billion.
As Bertagnolli steps in, NIH and FDA reenvision clinical trials and evidence generation
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding.
At the end of July, after just a few months as director of the Center for Biologics Evaluation and Research, Vinay Prasad resigned.
To fight drug shortages that have dogged all of medicine—including oncology—for decades, the Trump administration is returning to a policy it first enacted during the president’s first term.
FDA is shortening its timeline for publicizing Complete Response Letters, pledging to make them available to the public “promptly” after sponsors receive notice.
Julie BaumanRyan BurriNRG Oncology, an NCI National Clinical Trials Network group focused on multi-center clinical research, appointed Julie Bauman as deputy chair of the Community Oncology Research Program.
